15-Hydroxyprostaglandin dehydrogenase is downregulated and exhibits tumor suppressor activity in gastric cancer

Cancer Investigation

Volumn 29, Issue 4, 2011, Pages 257-265

  Song, Ho June ^a,b   Myung, Seung Jae ^a,b   Kim, In Wha ^a   Jeong, Jin Yong ^a   Park, Young Soo ^b   Lee, Sun Mi ^a   Nam, Won Hee ^a   Ryu, Yeon Mi ^a   Fink, Stephen P ^c   Yang, Dong Hoon ^a,b   Jung, Hwoon Yong ^a,b   Kim, Jin Ho ^a,b,d  

^a Asan Institute for Life Sciences   (South Korea)

^b Asan Medical Center   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

15 hydroxyprostaglandin dehydrogenase; Prostaglandin E2; Stomach neoplasm

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DNA VECTOR; ENZYME ACTIVITY; GASTRITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; WILD TYPE;

ADENOMA; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DINOPROSTONE; DOWN-REGULATION; GASTRITIS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; METAPLASIA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PRECANCEROUS CONDITIONS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 79953802545     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.568562     Document Type: Article

References (34)

1. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-1226. (Pubitemid 29473315)
2. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-122. (Pubitemid 41820645)
3. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev 2001;1:11-21. (Pubitemid 33741877)
4. Cha YI, DuBois, RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2006;58239-252.
5. Solomon SD,McMurray, JJ, PfefferMA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080. (Pubitemid 40365348)
6. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-1899. (Pubitemid 29272670)
7. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102. (Pubitemid 40365350)
8. Tai HH, Ensor CM, Tong M, Zhou H, Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 2002;68-69:483-493. (Pubitemid 35247416)
9. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 2006;103:12098-12102. (Pubitemid 44215817)
10. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, LawrenceE,Lutterbaugh J, Lu S,WillsonJK, LuoG,Hensold J, Tai HH, Wilson K, Markowitz SD. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 2004;101:17468-17473. (Pubitemid 39657428)
11. BacklundMG,Mann JR,HollaVR, Buchanan FG, TaiHH,Musiek ES, Milne GL, Katkuri S, DuBois, RN. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217-3223. (Pubitemid 40223783)
12. Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005;26:65-72. (Pubitemid 40207700)
13. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, Koeffler HP. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006;66:7818-7823. (Pubitemid 44289243)
14. Jemal A, Siegel R,WardE,MurrayT, Xu J,ThunMJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
15. Saukkonen K, Nieminen O, van Rees B, Vilkki S, Harkonen M, Juhola M, Mecklin JP, Sipponen P, Ristimaki A. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinaltype gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-1931. (Pubitemid 32994826)
16. Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factorHuR. Clin Cancer Res 2005;11:7362-7368. (Pubitemid 41507695)
17. Liu Z, Wang X, Lu Y, Han S, Zhang F, Zhai H, Lei T, Liang J, Wang J, Wu K, Fan D. Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis 2008;29:1219-1227. (Pubitemid 351958702)
18. Thiel A, Ganesan A, Mrena J, Junnila S, Nykanen A, Hemmes A, Tai HH,Monni O, Kokkola A, Haglund C, Petrova TV, Ristimaki A. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res 2009;15:4572-4580.
19. Yoo NJ, Jeong EG, Lee SH. Expression of 15-hydroxyprostaglandin dehydrogenase, a COX-2 antagonist and tumour suppressor, is not altered in gastric carcinomas. Pathology 2007;39:174-175.
20. Correa P,Houghton J. Carcinogenesis ofHelicobacter pylori. Gastroenterology 2007;133:659-672. (Pubitemid 47187360)
21. Mann JR, Backlund MG, Buchanan FG, Daikoku T, Holla VR, Rosenberg DW, Dey SK, DuBois RN. Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res 2006;66:6649-6656. (Pubitemid 44085621)
22. Yang L, Amann JM, Kikuchi T, Porta R, Guix M, Gonzalez A, Park KH, Billheimer D, Arteaga CL, Tai HH, DuBois R, Carbone DP, Johnson DH. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in nonsmall-cell lung cancer. Cancer Res 2007;67:5587-5593. (Pubitemid 46984987)
23. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-1280. (Pubitemid 27152551)
24. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 2001;84:965-968. (Pubitemid 32385841)
25. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB,West AB, RotterdamH, Fraumeni JF, Blot WJ.Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102. (Pubitemid 28109839)
26. Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 2004;23:1669-1678. (Pubitemid 38579527)
27. Saukkonen K, Tomasetto C, Narko K, Rio MC, Ristimaki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res 2003;63:3032-3036. (Pubitemid 36735846)
28. Breyer RM, Kennedy CR, Zhang Y, Breyer MD. Structurefunction analyses of eicosanoid receptors. Physiologic and therapeutic implications. Ann N Y Acad Sci 2000;905:221-231. (Pubitemid 30255420)
29. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, Xu D, Rosenberg DW. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 2008;68:3251-3259.
30. Holla VR, BacklundMG, Yang P, Newman RA,DuBois RN. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila PA) 2008;1:93-99.
31. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, Zhou X, Liu D, Rerko RM, Willis J, Dawson D, Tai HH, Barnholtz-Sloan JS, Newman RA, Bertagnolli MM, Markowitz SD. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A 2009;106:9409-9413.
32. Tai HH, Ensor CM, Zhou H, Yan F. Structure and function of human NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase. Adv Exp Med Biol 2002;507:245-250. (Pubitemid 37330188)
33. Huang G, Eisenberg R, Yan M, Monti S, Lawrence E, Fu P, Walbroehl J, Lowenberg E,Golub T,Merchan J, TenenDG,Markowitz SD, Halmos B. 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res 2008;68:5040-5048.
34. Gee JR, Montoya RG, Khaled HM, Sabichi AL, Grossman HB. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol 2003;21:266-270. (Pubitemid 38542730)